Intellia Therapeutics (NTLA)

• Market cap: $687M
• 1 day: -6.61%
• 5 days: -23.24%
• 1 month: -29.74%
• 3 months: -45.66%
• 6 months: -65.42%
• Year to date: -45.66%
• 1 year: -75.61%
• 5 years: -40.39%
• 10 years: -69.95%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

43% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $11.5M

33% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 49

5.09% more ownership

Funds ownership: 92.39% [Q3] → 97.47% (+5.09%) [Q4]

4% more funds holding

Funds holding: 280 [Q3] → 291 (+11) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

39% less capital invested

Capital invested by funds: $1.93B [Q3] → $1.17B (-$758M) [Q4]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 66% upside
• Avg. target: $33 398% upside
• High target: $68 924% upside

11 analyst ratings

• positive: 7 64%
• neutral: 4 36%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 59 / 181 met price target	352% upside $30	Buy Initiated	5 Mar 2025
Truist Securities Joon Lee 54% 1-year accuracy 22 / 41 met price target	653% upside $50	Buy Maintained	4 Mar 2025
Barclays Gena Wang 20% 1-year accuracy 6 / 30 met price target	292% upside $26	Overweight Maintained	28 Feb 2025
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target	111% upside $14	Neutral Maintained	28 Feb 2025
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 17 met price target	653% upside $50	Overweight Maintained	28 Feb 2025